TJ9 Stock Overview Provides aesthetic and dermatology solutions for medical practitioners worldwide. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Cutera Historical stock prices Current Share Price US$0.37 52 Week High US$4.40 52 Week Low US$0.26 Beta 1.32 1 Month Change 1.62% 3 Month Change -44.40% 1 Year Change -85.75% 3 Year Change -98.88% 5 Year Change -98.90% Change since IPO -95.00%
Recent News & Updates
Cutera Receives Deficiency Notice from Nasdaq Regarding Minimum $15 Million Market Value of Publicly Held Shares Requirement under Nasdaq Marketplace Rule 5450(b)(3)(C) Nov 23
New major risk - Market cap size Nov 10
Cutera, Inc. Reaffirms Financial Guidance for the Full Year 2024 Nov 09
Cutera, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 08
Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1) Oct 02
Second quarter 2024 earnings released: US$1.23 loss per share (vs US$1.68 loss in 2Q 2023) Aug 09 See more updates
Cutera Receives Deficiency Notice from Nasdaq Regarding Minimum $15 Million Market Value of Publicly Held Shares Requirement under Nasdaq Marketplace Rule 5450(b)(3)(C) Nov 23
New major risk - Market cap size Nov 10
Cutera, Inc. Reaffirms Financial Guidance for the Full Year 2024 Nov 09
Cutera, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 08
Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1) Oct 02
Second quarter 2024 earnings released: US$1.23 loss per share (vs US$1.68 loss in 2Q 2023) Aug 09
Cutera, Inc. Revises Revenue Guidance for the Year 2024 Aug 09
High number of new and inexperienced directors Aug 01
Cutera, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26 Cutera, Inc.(NasdaqGS:CUTR) dropped from Russell 3000 Index
High number of new and inexperienced directors Jun 18 Cutera, Inc., Annual General Meeting, Jul 15, 2024
Cutera, Inc. Reiterates Earnings Guidance for 2024 May 10
Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 28
Cutera, Inc. Announces North America Launch of xeo+ Apr 12
Cutera, Inc. Provides Revenue Guidance for the Full Year 2024 Mar 22 Cutera, Inc. announced delayed annual 10-K filing Mar 19
Third quarter 2023 earnings released: US$2.22 loss per share (vs US$0.62 loss in 3Q 2022) Mar 06
Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 02
High number of new and inexperienced directors Feb 13 Cutera, Inc. Revises Revenue Guidance for the Full Year 2023 Jan 10
Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q Nov 17
Cutera, Inc. announced delayed 10-Q filing Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023
Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023 Oct 07
New minor risk - Market cap size Oct 06
Cutera, Inc. Appoints Brent Hauser as President, International Oct 05
Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO Sep 08
President recently bought €274k worth of stock Aug 31
Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023 Aug 25
Second quarter 2023 earnings released: US$1.59 loss per share (vs US$2.53 loss in 2Q 2022) Aug 09
Cutera, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023 Aug 02
Cutera, Inc. Announces CEO Changes, Effective August 7, 2023 Jul 28
Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 24
the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023 Jun 29
Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris Jun 16
Cutera, Inc. Announces Resignation of J. Daniel Plants as Director Jun 12
Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors Jun 08
Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc May 25
Less than half of directors are independent May 23
Cutera, Inc. Announces Board Changes May 20
Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer May 18
Voce Capital and David Mowry Terminate Proxy Solicitation May 16
Cutera, Inc. Announces Chief Financial Officer Changes May 11
First quarter 2023 earnings released: US$1.27 loss per share (vs US$0.84 loss in 1Q 2022) May 10
Full year 2022 earnings released: US$4.39 loss per share (vs US$0.12 profit in FY 2021) Apr 09
Now 26% undervalued after recent price drop Mar 02
Full year 2022 earnings released: US$4.39 loss per share (vs US$0.12 profit in FY 2021) Mar 01 Cutera, Inc. to Report Q4, 2022 Results on Feb 28, 2023
Cutera, Inc. Announces AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch Nov 08
Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.077 loss in 3Q 2021) Nov 05
Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022 Nov 04
Cutera, Inc. Announces Committee Appointments Nov 03
Cutera, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Cutera, Inc. Announces Resignation of Katherine S. Zanotti from the Board Sep 27
Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022 Aug 06
Second quarter 2022 earnings released: US$2.53 loss per share (vs US$0.43 profit in 2Q 2021) Aug 05
Cutera, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Cutera, Inc. Announces AviClear Secured Clearance from Health Canada Jul 14
Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022 May 12
First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.02 loss in 1Q 2021) May 11
Cutera, Inc., Annual General Meeting, Jun 15, 2022 May 03
Cutera Announces First Patient Treated with FDA Cleared Aviclear Acne Device Apr 06
High number of new directors Mar 29
CEO & Director recently bought €92k worth of stock Mar 08
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24
Cutera, Inc. Provides Revenue Guidance for the Year 2022 Feb 24
Cutera, Inc. to Report Q4, 2021 Results on Feb 22, 2022 Feb 01
High number of new directors Jan 02
CEO & Director recently bought €88k worth of stock Dec 05
Cutera Launches Next Gen Rapid Muscle Sculpting with truSculpt® Flex+ Dec 02
Third quarter 2021 earnings released: US$0.077 loss per share (vs US$0.13 loss in 3Q 2020) Nov 05
Executive Chairman recently bought €123k worth of stock Aug 20
Independent Director recently bought €69k worth of stock Aug 13
Second quarter 2021 earnings released: EPS US$0.43 (vs US$0.67 loss in 2Q 2020) Aug 05
Cutera, Inc. announced delayed annual 10-K filing Mar 18
Cutera, Inc. Announces Not to Provide Earnings Guidance for the Fiscal Year 2021 Feb 18
New 90-day high: €22.60 Feb 05
Cutera, Inc. to Report Q4, 2020 Results on Feb 17, 2021 Feb 03
New 90-day high: €21.40 Jan 21
Revenue beats expectations Nov 12
Third quarter 2020 earnings released: US$0.13 loss per share Nov 12
New 90-day high: €18.10 Nov 12
Third quarter 2020 earnings released: US$0.13 loss per share Nov 07
Revenue beats expectations Nov 07 Shareholder Returns TJ9 DE Medical Equipment DE Market 7D 24.0% -1.7% -0.4% 1Y -85.8% -6.8% 7.9%
See full shareholder returns
Return vs Market: TJ9 underperformed the German Market which returned 7.9% over the past year.
Price Volatility Is TJ9's price volatile compared to industry and market? TJ9 volatility TJ9 Average Weekly Movement 15.8% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: TJ9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TJ9's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.
Show more Cutera, Inc. Fundamentals Summary How do Cutera's earnings and revenue compare to its market cap? TJ9 fundamental statistics Market cap €9.48m Earnings (TTM ) -€139.46m Revenue (TTM ) €150.62m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TJ9 income statement (TTM ) Revenue US$155.21m Cost of Revenue US$146.01m Gross Profit US$9.20m Other Expenses US$152.91m Earnings -US$143.71m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -7.12 Gross Margin 5.93% Net Profit Margin -92.59% Debt/Equity Ratio -166.3%
How did TJ9 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 03:28 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cutera, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Anup Mehta Canaccord Genuity Louise Chen Cantor Fitzgerald & Co. Jennie Tsai G. Research, LLC
Show 8 more analysts 
